eTheRNA immunotherapies NV is a clinical-stage company delivering innovative cancer immunotherapies from its proprietary mRNA-based TriMix platform. eTheRNA’s goal is to commercialize these immunotherapies to deliver long lasting clinical remission to cancer patients. eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium
eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology.
eTheRNA’s TriMix contains three naked mRNA molecules that combined work as a potent T-cell vaccine adjuvant:
TriMix is unique in the way it uses these three mRNA molecules to induce the proliferation of T-cells into either mature helper T-cells or cytotoxic T-cells – the ultimate ‘soldiers’ of the immune system that fight cancer cells and infectious agents. By combining TriMix with tumor-specific antigens or neoantigens the patient’s dendritic cells are stimulated to produce a more potent and larger population of antigen specific cytotoxic and helper T-cells compared to tumor antigens alone.
eTheRNA LNPs for intravenous delivery of mRNA have been show to exert first-in-class immune T-cell-specific responses in preclinical experiments. The induced immune responses are multifunctional and boostable. These premium results was achieved by optimizing the composition of the LNPs and designing them to target the spleen and not mainly the liver.
eTheRNA distinguishes itself from competitors on different levels:
© 2020 Etherna | Studio Hanswijk